Although the 2012 guideline from Kidney Disease: Improving Global Outcomes states that introduction of ESA therapy should be considered when Hb level decreases below 10 g/dL in patients with non-dialysis-dependent CKD [7], it provides no evidence to support this recommendation. The gene discussed is GSTM1; the disease is chronic kidney disease.